- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Wednesday's Options Recap
-
Our Monthly Buy / Sell List
-
Much Ado About Medarex
-
Is Medarex's Prostate Cancer Drug a Success? Too Early to Tell
-
Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great Promise
-
Medarex's 'Holy Grail' Against Prostate Cancer Causes Surge in Share Price
-
FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex
-
Monday's Options Recap
-
On Palm, Medarex, Walgreen and Oracle
-
FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM
-
FDA, Clinical Trial Updates: Pro-Pharma Looks Promising
-
Bright Prospects for Micromet (Part 2)
-
Pre-Market Report: Stocks on Course for Lower Start
-
Updated FDA, Clinical Trial Calendars: Dendreon Releases Results
-
Pequot Capital: Yet Another Hedge Fund Buying Gold
-
3 Top and Bottom Market Sectors for This Week
-
Hedge Fund Tracking: Barry Rosenstein's Jana Partners, Q3 2008
-
FDA Calendar Update: High Hopes for Amgen's Bone Drug
-
Three-Month, Updated FDA Decision Calendar
-
Ustekinumab PDUFA Could Kick Start Medarex Revival
-
FDA's "Risky Business" for Pharma & Biotech
-
What's Next For Medarex?
-
Medarex Plunges On Disappointing Ipilimumab Trial
-
Thursday's Options Report: Morgan, Merrill, JP Morgan, Citigroup, Medarex, Raytheon, Manpower, AstraZeneca, Jos Bank Clothiers
-
The "Naked" Truth About Antibodies For Cancer Therapy
-
Cancer Stocks Slide Again
-
Cancer Stocks Plunge Following ASCO Meeting
-
Cancer Stocks Soar With Annual ASCO Meeting
-
Cancer Stocks on the Go: Winners and Losers
-
Biotech Day in Review: Allergan Expands Obesity Franchise
-
Biotech Day in Review: Shire Buys New River for $2.6 Billion
-
The Future Looks Golden for Medarex
-
Biotech Week-in-Review: Genentech, Amgen Take a Toll on Biotech
-
Biotech Stocks Day-In-Review: Coley Drops After Ending Hepatitis C Program
-
Biotech Stocks Review: Amphora Sells Oncology Program to Genentech
-
Biotech Stocks Day-in-Review: BioCryst Gets Flu Drug Support
-
Updated WSJ Options Scandal Scorecard
-
WSJ Options Scandal Scorecard